Sirius Therapeutics
Latest round
- Series B
Last raised
- May 2025
Total raised
- $110M
Investors
- 5
About Sirius Therapeutics
Based in Shanghai, China, and founded in 2022, Sirius Therapeutics operates as a pharmaceutical R&D service provider, focusing on the development of innovative nucleic acid therapies in the field of cardiovascular diseases. It has set up an innovation research and development center in the USA. The company's CEO, Ji Qunsheng, studied at Vanderbilt University and Peking Union Medical College in the United States. The company focuses on the development of innovative nucleic acid therapies in the field of cardiovascular diseases, and its main products are small nucleic acid drugs. The product pipeline includes SRSD107 injection, SRSD101, and SRSD216. SRSD101 is a PCSK9 siRNA drug, mainly suitable for hypercholesterolemia and atherosclerotic cardiovascular disease. SRSD216 is a siRNA therapy for the treatment of hyperlipoproteinemia (a). Sirius Therapeutics has developed a core technology platform that can be used for the research and development of small nucleic acid drugs. The company generates revenue by providing innovative nucleic acid therapies in the field of cardiovascular diseases, such as SRSD107 injection and SRSD101.
Who invested in Sirius Therapeutics
5 investors across 2 rounds
See all investors in Sirius Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sirius Therapeutics
Who invested in Sirius Therapeutics?
Sirius Therapeutics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sirius Therapeutics raised?
Sirius Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Sirius Therapeutics last raise money?
Sirius Therapeutics's most recent round on record is a Series B, in May 2025.
What does Sirius Therapeutics do?
Based in Shanghai, China, and founded in 2022, Sirius Therapeutics operates as a pharmaceutical R&D service provider, focusing on the development of innovative nucleic acid therapies in the field of cardiovascular diseases.
Where is Sirius Therapeutics headquartered?
Sirius Therapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like Sirius Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Sirius Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Sirius Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.